We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2022 to Jul 2024
By Colin Kellaher
Replimune Group Inc. on Tuesday said it inked a deal to work with Swiss pharmaceutical company Roche Holding AG to advance Replimune RP2/3 program in colorectal cancer and hepatocellular carcinoma.
Replimune said Roche would share costs to develop RP3 in combination with Roche's cancer drugs Tecentriq and Avastin in third-line colorectal cancer and in second-line hepatocellular carcinoma.
Replimune, a Woburn, Mass., clinical-stage biotechnology company, said Roche would also supply Tecentriq and Avastin for combination studies of RP3 in first-line hepatocellular carcinoma and RP2 in third-line colorectal cancer.
Replimune, which has similar collaborations in place for its lead candidate RP1 with Regeneron Pharmaceuticals Inc. and Bristol Myers Squibb Co., said it is on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 07, 2022 07:29 ET (12:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
